Wed, April 4, 2012
Tue, April 3, 2012
[ Tue, Apr 03rd 2012 ] - Market Wire
EntreMed Appoints Interim CEO
Mon, April 2, 2012
Sun, April 1, 2012
Sat, March 31, 2012
Fri, March 30, 2012
Thu, March 29, 2012
Wed, March 28, 2012
Tue, March 27, 2012
Mon, March 26, 2012
Sun, March 25, 2012
Sat, March 24, 2012
Fri, March 23, 2012
Thu, March 22, 2012
[ Thu, Mar 22nd 2012 ] - Market Wire
30 p.m. ET

Omeros to Present at Two Upcoming Conferences


//health-fitness.news-articles.net/content/2012/ .. eros-to-present-at-two-upcoming-conferences.html
Published in Health and Fitness on Wednesday, March 28th 2012 at 13:11 GMT by Market Wire   Print publication without navigation


Omeros to Present at Two Upcoming Conferences -- SEATTLE, March 28, 2012 /PRNewswire/ --

Omeros to Present at Two Upcoming Conferences

[ ]

SEATTLE, March 28, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: [ OMER ]), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences:

11th Annual Needham Healthcare Conference
April 4, 2012
10:00 a.m. EDT
New York, NY

Future Leaders in the Biotech Industry Conference
April 20, 2012
10:00 a.m. EDT
New York, NY

The presentations will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at [ www.omeros.com ].  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation

[ Back to top ]

RELATED LINKS
[ http://www.omeros.com ]


Publication Contributing Sources